Pyrimidine derivatives and their use as CB2 modulators

Details Pyrimidine derivatives and their use as CB2 modulators Pyrimidine derivatives and their use as CB2 modulators

2003-08-19

2009-12-22

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S330000, C544S331000

Reexamination Certificate

active

07635701

ABSTRACT:
The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

REFERENCES:
patent: 5112820 (1992-05-01), Ward et al.
patent: 5811428 (1998-09-01), Suto et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 6107301 (2000-08-01), Aldrich et al.
patent: 6184237 (2001-02-01), Mantlo et al.
patent: 0569912 (1993-11-01), None
patent: 0576357 (1993-12-01), None
patent: 2839718 (2003-11-01), None
patent: WO 97/09315 (1997-03-01), None
patent: WO 00/39101 (2000-07-01), None
patent: WO 02/04429 (2002-01-01), None
patent: WO 02/060447 (2002-08-01), None
patent: WO 02/062750 (2002-08-01), None
patent: WO 02/066036 (2002-08-01), None
patent: WO 2004/000807 (2003-12-01), None
patent: WO 2004/018433 (2004-03-01), None
patent: WO 2004/018434 (2004-03-01), None
patent: WO 2004/029026 (2004-04-01), None
patent: WO 2004/029027 (2004-04-01), None
patent: WO 2004/029204 (2004-04-01), None
patent: WO 2004/002964 (2004-08-01), None
patent: WO 2004/085385 (2004-10-01), None
Souness, J.E. “Immunosuppressive And Anti-flammatory Effect of Cyclic AMP.” Immunopharmacology, 2000, 47/2-3; 127-162.
Huang, Z., et al. “Next Generation of PDE4 Inhibitors.” Current Opinion in Chemical Biology, 2001, pp. 432-438.
Sullivan, R. W., et al. 2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3′,5′-bis(trifluoromethyl)phenyl-carboxamic Potent Inhibitor of NF-KB-and AP-1-Mediated Gene Expression Identified Using Solution-Phase Combinatorial Chemistry; J. Med. Chem.; 1998; 41; 413-419.
Huffman, J.W. “The Search For Selective Ligands For The CB2 Receptor.” Currently Pharmaceutical Design, Bentham Science Publishers, vol. 6., No. 13, 2000, pp. 1323-1337.
Gerard M.P. Giblin et al; Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain.; J.Med Chem; 2007; 50; 2597-2600; American chemical society; USA.
Hatzelmann, A. et al.; “Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE4 Inhibitor Roflumilast In Vitro.”; Journal of Pharmacology and Experimental Therapeutics; 2001; 297 (1); 267-279.
Iwamura H. et al.; “In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.”; Journal of Pharmacology and Experimental Therapeutics; 2001; 296(2); 420-425.
Malan, T.P. et al.; “CB2 Cannabinoid Receptor Agonists: Pain Relief Without Psychoactive Effects?”; Current Opinion in Pharmacology; 2003; 3; 62-67.
Van Der Mey M. et al.; “Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.”; Journal of Pharmacology and Experimental Therapeutics; 2001; 45(12); 2520-2525.
Hohmann, A.G. et al.; “Spinal and Peripheral Mechansims of Cannabinoid Antinociception: Behavioral, Neurophysiological and Neuroanatomical Perspectives”; Chemistry and Physics of Lipids; 2002; 121; 173-190.
Farquhar-Smith, W.P. et al.; “Administration of Endocannabinoids Prevents a Referred Hyperalgesia Associated with Inflammation of the Urinary Bladder”; Anesthesiology; 2001; 94; 507-513.
Jaggar, S.I. et al.; “The Anti-Hyperalgesic Actions of the Cannabinoid Anandamide and the Putative CB2 Receptor Agonist Palmitoylethanolamide in Visceral and Somatic Inflammatory Pain”; Pain; 1998; 76; 189-199.
Kehl, L.J. et al.; “A cannabinoid Agonist Differentially Attenuates Deep Tissue Hyperalgesia in Animal Models of Cancer and Inflammatory Muscle Pain”; Pain; 2003; 103; 175-186.
Goya, P. et al.; “Cannabinoids and Neuropathic Pain”; Mini Reviews in Medicinal Chemistry; 2003; 3; 765-772.
Yao, B.B. et al.; “In Vitro and In Vivo Characterization of A-796260: A Selective Cannabinoid CB2 Receptor Agonist Exhibiting Analgesic Activity in Rodent Pain Models”; British Journal of Pharmacology; 2008; 153; 390-401.
Pertwee, R.G. et al.; “Cannabinoid Receptors and Pain”; Progress in Neurobiology; 2001; 63; 569-611.
Jhaveri, M.D. et al.; “Cannabinoid CB2 Receptor-Mediated Anti-nociception in Models of Acute and Chronic Pain”; Molecular Neurobiology; 2007; 36; 26-35.
Izzo A.A. et al.; “The Cannabinoid CB2 Receptor: A Good Friend in the Gut”; Neurogastroenterology Motility; 2007; 19; 704-708.
Malan, T.P. et al.; “Inhibition of Pain Responses By Activation of CB2 Cannabinoid Receptors”; Chemistry and Physics of Lipids; 2002; 121; 191-200.

Affiliated with

Also associated with

Rating

Pyrimidine derivatives and their use as CB2 modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrimidine derivatives and their use as CB2 modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine derivatives and their use as CB2 modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4067936